Nuvation Bio Engages in Upcoming Investor Conferences to Highlight Cancer Innovations
Nuvation Bio Engages in Upcoming Investor Conferences to Highlight Cancer Innovations
Nuvation Bio Inc. (NYSE: NUVB), a prominent player in the oncology sector, has announced its participation in two significant investor conferences this September. These events are an opportunity for the firm to showcase their groundbreaking work in addressing some of the most challenging issues faced in cancer treatments.
Conference Details
The upcoming conferences where Nuvation Bio will be represented include:
1. Citi's 2026 Biopharma Back to School Conference: This event is scheduled for Wednesday, September 9, 2026, at 9:20 a.m. ET, taking place in New York City.
2. 2026 Cantor Global Healthcare Conference: This will follow on Thursday, September 10, 2026, at 1:35 p.m. ET, also held in New York City.
David Hung, M.D., the visionary Founder, President, and CEO of Nuvation Bio, along with Philippe Sauvage, the Chief Financial Officer, will lead discussions in fireside chats and meet with investors.
Live Broadcasts and Accessibility
For investors and stakeholders unable to attend in person, both fireside chats will be accessible through live webcasts. These webcasts will be hosted on the Investor Relations section of the Nuvation Bio website, with a recording available for 90 days following each event. This ensures that anyone interested can catch up on the insights shared during these discussions.
About Nuvation Bio
Founded in 2018, Nuvation Bio is dedicated to overcoming the significant hurdles in cancer treatment. They are focused on developing therapies that have a meaningful impact on patient outcomes. Their portfolio boasts a diverse range of innovative treatments, which include:
- - Taletrectinib (IBTROZI®): A next-generation ROS1 inhibitor showing promise in targeted cancer therapy.
- - Safusidenib: This brain-penetrant IDH1 inhibitor is designed for certain types of cancers affecting the brain.
- - Drug-Drug Conjugate (DDC) Program: Their novel approach takes aim at improving drug delivery methods, thus enhancing treatment efficacy.
The company has offices in major cities including New York, San Francisco, Boston, and Shanghai, which facilitates their global outreach and collaboration efforts in the oncology field.
Conclusion
With these upcoming investor conferences, Nuvation Bio is poised to not only expand its visibility but also strengthen its relationships within the investment community. Their commitment to advancing cancer treatment solutions is reflected in their strategic engagements and the innovative therapies they are developing. Interested parties can learn more about Nuvation Bio and their initiatives by visiting their official website or following them on social media platforms.
For media inquiries, Nuvation Bio can be contacted directly via their investor and media relations teams.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.